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Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial
Background Certain antihypertensive medications appear to alter Alzheimer's disease (AD) biomarkers in Caucasians and African Americans [1, 2] . The renin angiotensin system (RAS) regulates blood pressure (BP) and fluid maintenance in the body and the brain, and may directly influence AD biomarkers, including Aβ and tau, cerebral blood flow (CBF) and inflammatory markers [3] [4] [5] . This hypothesis is supported by studies showing that antihypertensives targeting the RAS, that most commonly are angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (A2RBs), reduce the risk and slow the progression of clinical AD [6] [7] [8] . We have shown that 1) blood brain barrier (BBB) crossing RAS medications exert protective cognitive effects and slow disease progression in hypertensive individuals with MCI, and 2) BBB crossing RAS medications are able to significantly alter brain RAS levels in middle aged Caucasians at risk for AD due to a parental history [9] .
While mounting evidence supports a protective role of RAS medications in Caucasians, this mechanism has not been clinically tested in African Americans. We recently published a metaanalysis that reported the rate of AD incidence is 64% higher for African Americans than for Caucasians [10] . Moreover, we estimated the current U.S. AD prevalence for ages 65-90 to be 5.5% for Caucasians, and 8.6% for African Americans (prevalence ratio 1.56). Thus, not only are African Americans more likely to become afflicted with AD, they are also living longer with the disease. Because African Americans are at higher risk for AD than Caucasians, and RAS medications have shown to positively influence AD biomarkers and clinical disease progression, the potential benefit of RAS acting medications in this high risk population needs to be addressed.
African Americans are at higher risk for vascular risk factors, including hypertension, which independently contributes to cognitive impairment and AD, possibly via RAS regulation [11] .
African Americans have lower circulating renin and higher aldosterone and sodium levels than Caucasians, and therefore RAS antihypertensives, which are those medications believed to exert AD-related benefits in Caucasians, are not indicated for African Americans, though safety and efficacy studies of RAS acting medications show that they are well tolerated [12, 13] . If RAS medications are prescribed, higher doses are generally required to achieve comparable BP control to that seen in Caucasians at lower doses. Importantly, the dose needed to alter RAS levels in the brain is unknown, and may be lower than the dose required to alter BP, as suggested by observed benefits of an ARB on cognitive decline that were independent of changes in BP.
While many researchers now argue that prescription practices based on race are unwarranted, these trends persist in clinical practice and were upheld in the JAMA Guidelines for the treatment of hypertension in 2014 [14] . Because we know that the brain RAS is implicated in AD neuropathology and we can manipulate this system in the brains of Caucasians [15] , we are investigating whether RAS medications confer similar AD-related benefits in African Americans, and whether we can clinically alter this system, and at what dose.
We previously reported that individuals taking RAS acting medications (ACE-Is or A2RBs), particularly those that are centrally acting, show slower cognitive decline and are less likely to progress from MCI to AD over three years [16] . However, the potential mechanism was unclear due to the absence of neuropathological findings, although results are consistent with studies of post-mortem brain tissue of AD patients, that point to elevations of angiotensin converting enzyme (ACE), that both ACE-Is and A2RBs are designed to mitigate [17] . More recently, we confirmed these results, and further reported that individuals taking RAS acting medications exhibited significantly fewer neurofibrillary tangles (NFT) than non-RAS users in 5 brain regions including the mid-frontal cortex, mid-temporal cortex, inferior parietal cortex, entorhinal cortex, and hippocampal CA1 region manuscript under review.).
Importantly, because Aβ and tau accumulation and RAS dysfunction begin during midlife, it is imperative to investigate these biomarkers in middle-aged, presymptomatic adults, while there is time to intervene, before the irreversible AD cascade begins. Further, exploring the potential benefit of using existing drugs (i.e. "repurposing") that are generally recognized as safe, such as RAS medications, shortens the time needed to demonstrate efficacy, and thus, more rapidly provides urgently needed treatment options for this devastating illness. vs placebo in African Americans, since they are commonly given higher RAS-acting medication doses to achieve BP control. Importantly, though African Americans are given higher doses for BP control, the dose required to cross the BBB and alter the brain RAS is unknown, and it is likely that this dose is lower than the dose required to alter BP in the body. Screening: Initial eligibility is determined via phone interview by a member of the HEART team, at which time a screening questionnaire and the Dementia Questionnaire are administered [19] .
This screening process explores a potential participant's match against the inclusion and Procedure Descriptions:
Arterial Function Assessment via Ultrasound -PWV: Pulse wave velocity (PWV) is noninvasive and is administered at Baseline and Month 8. This is a measure of arterial stiffness, which has been shown to be superior to clinical BP measures when predicting cognitive decline in healthy populations and may be more sensitive to BP medication changes than other measures [21] . PWV is a highly reproducible measure of artery wall stiffness and is strongly correlated with cardiovascular events and all-cause mortality. Both PWV and PWA are assessed using measurements of the radial, carotid, and femoral arteries, using the SphygmoCor Pulse Wave Velocity system (PWV Medical). In brief, peripheral pressure waveforms were recorded from the radial artery at the wrist, using applanation tonometry with a high-fidelity micromanometer. lidocaine is used as a local anesthetic, followed by insertion of a spinal needle with introducer into the L4-L5 interspace using sterile technique. Using a 24 gauge Sprotte needle and a gentle extraction technique, approximately 22 ml of CSF is collected using sterile polypropylene collection tubes. Samples undergo a 10 minute 2500rpm spin and are aliquoted into 500µl polypropylene cryovials and stored at -80 for future assays, which will take place after all participants complete Baseline LP and bathed and tested again after all Month 8 CSF is collected.
CSF Biomarkers:
(i) RAS measures: To determine the extent to which telmisartan may penetrate the CNS, we will analyze key RAS components (such as ACE, angiotensin I, II, III, IV and ACE2) at Baseline and Month 8.We will use established methods including ELISA and activity assays using specific fluorogenic substrates [23] [24] [25] which, when coupled with the RAS measures collected in plasma, will provide the most comprehensive characterization of systemic and brain RAS function in African Americans to date.
(ii) Tau and Abeta: CSF T-tau concentration is determined using a sandwich ELISA (Innotest hTAU-Ag, Innogenetics, Ghent, Belgium) specifically constructed to measure all tau isoforms irrespective of phosphorylation status [23] . Tau phosphorylated at threonine 181 (P-tau)
was measured using a sandwich ELISA method (INNOTEST® PHOSPHO-TAU (181P), Innogenetics, Ghent, Belgium) [24] . Aβ1-42 levels will be determined using a sandwich ELISA (INNOTEST® β-AMYLOID(1-42), Innogenetics, Gent, Belgium), specifically constructed to measure Aβ containing both the first and 42nd amino acid [25] . Samples will be assayed in one batch after study completion by Dr. Zetterberg, an expert in CSF AD biomarkers. Dr. Zetterberg has performed all of our CSF biomarkers in this same 'at risk' cohort. All assays are performed as singlicates because the measurements are well standardized. Assay stability is monitored throughout the sample series using quality control samples representing low and high biomarker concentrations. Plates with CVs of the quality samples higher that 15% will be re-analyzed. All assays are conducted by board-certified laboratory technicians blinded to participant clinical characteristics and randomization group. (i) RAS function: We measure, using established methods [23, 25] , RAS components that focus around the generation (ACE) and degradation (ACE2) of angiotensin II to determine the levels of RAS activity that is mediated through angiotensin II, the primary mediator of RAS.
(ii) ApoE Genotyping: Venous blood is collected into EDTA anticoagulated tubes and genomic DNA is isolated by standard protocols. We isolate 50 to 70g of DNA from 2 mL of whole blood. APOE genotypes are determined by real-time polymerase chain reaction using We have previously reported an association between inflammation and cognitive performance in African Americans than Caucasians, and have recently reported higher levels of inflammation in both blood and CSF in a middle age cohort at risk for AD [26, 28] . [38] , and language (Multilingual Naming Test (MINT)) [39] .
Questionnaires: The following information is collected from participants at Baseline and Month 8. Most questionnaires are computerized using the RedCap system and emailed to participants before their Baseline and Month 8 visits, so participants can complete them at their leisure and to cut down on study visit duration. Questionnaires include information pertaining to: (i) medical and medication history; (ii) exercise [40] ; (iii) sleep [41] ; (iv) nutrition [42] ; (v) positive [43, 44] and negative (stress) aspects of caregiving [45] [46] [47] ; (vi) depression [48] ; and (vii) behavior and quality of life of their parent with AD [49, 50] .
Adverse events (AE) and Data Safety and Monitoring: HEART is approved by the Emory 
Analyses and Power Calculations
We will conduct Wilcoxon-Mann-Whitney tests to assess whether the change in the level of each CSF biomarker (Month 8 vs Baseline) differs between the treated group and placebo group.
Tests will be conducted separately for each dose group (20 mg and 40 mg) but we will also consider testing for a dose-response by conducting Jonckheere-Terpstra trend tests. P-values < 0.05 will be regarded as significant for the primary outcomes (CSF Aβ, tau, ACE). We will use
False discovery Rate (FDR) correction to adjust p values for all secondary outcomes. We will use a 0.025 alpha level for all outcomes, which is in accordance with the FDR. We will consider linear regression analysis (outcome is 8-month change in a biomarker) to adjust for demographic or clinical confounders. Demographic covariates will include age, education and gender. Clinical covariates will correspond to the appropriate outcomes, and will include, but are not limited to, ApoE 4 status, blood pressure, and depression. Power calculations for ACE, CBF, Aβ and tau comparisons are based on data from previous trials in similar populations. With 20 participants per group, we will have 99% power to detect change in ACE levels and 80% power to detect differences in CSF Aβ, tau and CBF between the treated groups and placebo (based on 2-sided tests and Type I error rate α =0.05).
Conclusion:
With the increasing incidence and prevalence of AD, research efforts should target high-risk groups in order to prevent or slow disease progression in tandem with cure-driven research directives in established disease. Repurposing existing medications that have been shown to be beneficial in observational and clinical trials is a cost effective way of slowing AD, particularly in high-risk individuals, and allow for more rapid research trajectories over conventional drug discovery approaches [51] . While longer interventions are optimal in healthy controls, early intervention is critical and assessing the impact on biomarkers in addition to cognitive changes is also of great importance. Because we know that the brain RAS is implicated in AD neuropathology in Caucasians, research should clinically investigate the extent to which RAS medications confer AD-related benefits in African Americans via the same mechanism, and the rate at which they do so. The HEART trial will provide data to address these issues.
